Scientific Publications by FDA Staff
Cancer Lett 2013 Aug 19;336(2):379-89
SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/beta-catenin signal network.
Li X, Xu Y, Chen Y, Chen S, Jia X, Sun T, Liu Y, Li X, Xiang R, Li N
SOX2 was reported to promote metastasis in various tumor tissues; however the underlying mechanisms remain elusive. Here, we disclosed that SOX2 improves metastasis of breast and prostate cancer cells by promoting epithelial-to-mesenchymal transition (EMT) through WNT/beta-catenin, but not TGF-beta or Snail1 signaling. Dual luciferase assay and chromatin immunoprecipitation revealed activation and binding of SOX2 on promoter region of beta-catenin. In addition, SOX2 affects the protein expression levels of DKK3, DVL1 and DVL3, which are regulators or downstream molecules of WNT signaling. Taken together, our findings demonstrated beta-catenin as one of vital downstream molecules that mediate the EMT induced by SOX2.
|Category: Journal Article|
|PubMed ID: #23545177||DOI: 10.1016/j.canlet.2013.03.027|
|Includes FDA Authors from Scientific Area(s): Toxicological Research|
|Entry Created: 2013-08-25|